Etretinate (CAS 54350-48-0)
QUICK LINKS
Etretinate is a aromatic retinoid that functions as a potent modulator of cell growth and differentiation. It exerts its mechanism of action by binding to nuclear retinoic acid receptors, retinoic acid receptor (RAR) and retinoid X receptor (RXR), which are transcription factors that regulate gene expression. This binding leads to the activation or repression of target genes involved in cellular differentiation, proliferation, and apoptosis. Etretinate′s interaction with these receptors ultimately results in the modulation of various cellular processes, including the regulation of keratinocyte proliferation and differentiation. It may influence the expression of genes involved in lipid metabolism and immune response. Etretinate′s mechanism of action at the molecular level may be valuable for investigating the role of retinoids in cellular processes and gene regulation.
Etretinate (CAS 54350-48-0) References
- Pharmacokinetics and drug interactions of etretinate and acitretin. | Lambert, WE., et al. 1992. J Am Acad Dermatol. 27: S19-22. PMID: 1460119
- Combination-therapy cyclosporin-A--etretinate for psoriasis. | Korstanje, MJ. and van de Staak, WJ. 1990. Clin Exp Dermatol. 15: 172-3. PMID: 2364569
- The pharmacokinetics of etretinate and its metabolites in the dog. | Thongnopnua, P., et al. 1989. Drug Metab Dispos. 17: 473-80. PMID: 2573489
- Etretinate. Persistent serum levels after long-term therapy. | DiGiovanna, JJ., et al. 1989. Arch Dermatol. 125: 246-51. PMID: 2913962
- Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. | Larsen, FG., et al. 1988. Pharmacol Toxicol. 62: 159-65. PMID: 2967472
- Pharmacokinetics of tazarotene and acitretin in psoriasis. | Heath, MS., et al. 2018. Expert Opin Drug Metab Toxicol. 14: 919-927. PMID: 30134735
- Acrokeratoelastoidosis treated with etretinate. | Handfield-Jones, S. and Kennedy, CT. 1987. J Am Acad Dermatol. 17: 881-2. PMID: 3680676
- Etretinate therapy in generalized pustular psoriasis (Zumbusch type). Immediate and long-term results. | Wolska, H., et al. 1985. Dermatologica. 171: 297-304. PMID: 3908171
- Etretinate therapy for psoriasis and other keratinizing disorders: a 10-year retrospective study in Singapore. | Shahidullah, M., et al. 1993. Int J Dermatol. 32: 686-9. PMID: 7691773
- Teratogenic risk with etretinate and acitretin treatment. | Geiger, JM., et al. 1994. Dermatology. 189: 109-16. PMID: 8075435
- Acitretin and etretinate. How and when they should be used. | Geiger, JM. and Saurat, JH. 1993. Dermatol Clin. 11: 117-29. PMID: 8435906
- Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. | Larsen, FG., et al. 1993. J Invest Dermatol. 100: 623-7. PMID: 8491984
- [Trans-acitretin is metabolized back to etretinate. Importance for oral retinoid therapy]. | Almond-Roesler, B. and Orfanos, CE. 1996. Hautarzt. 47: 173-7. PMID: 8647698
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Etretinate, 25 mg | sc-205689 | 25 mg | $92.00 | |||
Etretinate, 100 mg | sc-205689A | 100 mg | $224.00 |